Healthy Clinical Trial
Official title:
Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound
Renal parenchymal blood flow can be divided in cortical and medullary blood flow. Changes and factors affecting renal medullary blood flow have not been studied in detail previously as investigators/doctors did not have tools to monitor renal medullary blood flow in vivo. Since Trueta first described renal medullary blood flow, multiple attempts have been made to study renal medullary blood flow using invasive methods. Recently renal medullary blood flow measurement using contrast US has emerged as a promising technique that investigators can use to study renal medullary blood flow in vivo. In this study investigators are aiming to study changes in renal parenchymal (cortical and medullary) blood flow with exercise in healthy subject.
This study requires a screening day and two visits on separate days to the Clinical Research
Unit (CRU). Three visits total.
Screening Visit:
1. The subjects will undergo detailed history and physical examination.
2. The inclusion and exclusion criteria will be reviewed.
3. The details of the study procedures, potential risks and benefits will be reviewed with
each subject and all potential questions will be answered.
4. Subjects' understating of all details of the study components will be ascertained and
they will be asked to sign the informed consent form.
5. A copy of the signed informed consent will be placed in study file and another copy
will be provided to each subject.
6. The study visit day will be scheduled within 2 weeks of the screening day.
7. All subjects will be asked to arrive on their first study day after an overnight fast.
They will be instructed to avoid caffeine and exercise for 24 hours.
Study Day #1 The subjects will arrive in the CRU in the morning. Subjects' understanding of
all study related procedures will be assessed and all remaining questions will be answered.
The following sequence of procedures will be followed for all enrolled subjects.
1. Physical exam including vital signs (Blood Pressure, Heart Rate, Weight, Height,
Respiration Rate, Temperature)
2. Urine pregnancy test for women of child bearing age. If positive, subjects will be
excluded.
Determination of peak oxygen consumption
3. Subjects will complete a continuous VO2 peak bicycle ergometer protocol.
1. Each subject will start peddling on a stationary bike
2. The initial power output (PO) will be set at 20 watts
3. The power output will be increased by 15 watts every 2-minutes until volitional
exhaustion.
4. Metabolic data will be collected during the protocol using standard open-circuit
spirometric techniques (Viasys Vmax Encore, Yorba Linda, CA)
5. Heart rate was assessed electrocardiographically.
6. VO2 peak will be chosen as the highest VO2 attained during the exercise protocol
On Day 2 of testing
1. Check Vitals (BP, HR, Wt., RR, Temp.)
2. Insert peripheral IV line Baseline renal blood flow measurement using contrast enhanced
ultrasonography
3. The Definity vial will be placed at room temperature before being used. It will be
activated after shaking the vial using Vialmax® for 45 seconds. It will be used
immediately after activation.
4. 0.4 ml of Definity will be mixed in 10 ml of preservative free saline.
5. Infusion of Definity into a peripheral vein will be started at 2 ml/min and titrated
for optimal image quality using a minipump (not to exceed 10 ml/min at any time).
6. Baseline contrast ultrasound imaging of right kidney will be performed with low
mechanical index (MI) of 0.2.
7. 4 - 5 ultrasound impulses with high MI of 1.0 and duration of 1 second will be used to
destruct the microbubbles in the kidney tissue
8. Ultrasound imaging of the kidney with low MI (0.2) will continue immediately after each
impulse for several seconds.
9. Infusion of Definity will stop at this point.
10. Vital signs will be monitored every 15 minutes and continuous pulse oximetry will be
performed during Definity administration.
11. Vital signs and pulse oximetry will be monitored every 15 minutes until 30 minutes
after discontinuation of Definity.
12. A urine dipstick will be performed by the study team 30 minutes after completion of
Definity infusion if a sample is available.
Constant load Exercise protocol
13. Subjects will complete 30 minutes of continuous cycling at the power output associated
with 85% of VO2peak from the continuous bicycle ergometer protocol. Metabolic data will
be collected as described above.
14. Once metabolic parameter are reached, exercise will be stopped and subject will be
asked to lie down on the bed Renal Blood flow measurement following exercise using
contrast enhanced ultrasonography
15. Immediately after completion of exercise protocol, steps 5 - 12 under day 2 procedures
will be repeated.
16. The study procedures will end at this point.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |